A Combination Treatment Reduces Acne Severity and PIHP

Cosmetique Active

Status: Completed

Conditions: Acne; Postinflammatory Hyperpigmentation

Treatments: Other: anti-acne dermocosmetic

Study type: Observational

Funder types: Industry

Identifiers

NCT05601960

LRP19009

Details and patient eligibility

About

Acne is a chronic, inflammatory skin condition. It may cause scars and post-inflammatory hyperpigmentation (PIHP). PIHP frequently affects individuals with a phototype of IV or above.[1] PIHP is worsened by UV radiation, lasts for years and impacts the individual well-being.[2, 3] In an observational study, 1785 adults with a phototype ranging from IV to VI with acne and PIHP applied daily for 2 months a dermocosmetic and a tainted sunscreen product (DC, Effaclar® Duo (+); SS, Anthelios® Shaka Fluide SPF 50+, SS; both La Roche-Posay Laboratoire Dermatologique, France.

Enrollment: 1,785 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• adult
• mild to moderate acne
• presence of postinflammatory hyperpigmentation lesions
• phototype IV to VI

Exclusion criteria

• less than 18 years
• severe acne